Bariatric Surgery Volumes Declined 46% Over Three Years While GLP-1 Prescription Rates Increased
As use of glucagon-like peptide-1 receptor agonist (GLP-1) medications increased between 2022 and 2025, the volume of metabolic and bariatric surgeries (MBS) declined by 46.4% over three years, according to a recent study. Among people eligible for MBS, GLP-1 prescription rates increased from 0.22% in 2018 to 24.17% in the third quarter of 2025.
The study analyzed trends in the use of GLP-1 medications and bariatric surgery among adults eligible for MBS using electronic health record data.
MBS declined by 35% among those with a body mass index (BMI) of 55 or . . .
